Citizens JMP’s $40 target on SMMT

SMMT Summit Therapeutics

$16.9 → $40 (+137%) by Sep 2027

Market Outperform · reiterates · said Sep 30, 2026 · 12-month default horizon

Open: judged on the close on Sep 30, 2027

The article this target came from

Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

Investing.com · Sep 30, 2026

Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

Citizens JMP’s track record → Summit Therapeutics →

A fact about what Citizens JMP published, as reported by Investing.com, not a recommendation from Dalsna Finance; Citizens JMP is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.